Mazdutide
Clinical evidenceThe GLP-1/glucagon dual agonist that reached approval in China ahead of its Western rivals.
What it is
Mazdutide is a dual-agonist peptide built to hit the GLP-1 receptor for appetite and the glucagon receptor for energy use and liver fat. It is modeled on a natural gut hormone called oxyntomodulin. Chinese regulators approved it in 2025 for weight management and type 2 diabetes, though it is not yet approved in the US.
How it works
The GLP-1 half delivers the usual satiety and blood-sugar control. The glucagon half adds energy expenditure and a direct effect on the liver. Unlike the GIP-based drugs that dominate the market, this one pairs GLP-1 with glucagon and skips GIP.
What people report
- ✦About 14% average weight loss at the 6 mg dose over 48 weeks
- ✦About 20% at the higher 9 mg dose in a follow-up program
- ✦Approved in China for chronic weight management and type 2 diabetes
- ✦Proof that the GLP-1/glucagon mechanism can clear a regulator
Typical use
Used as a steady weight-management treatment; dosing is scaled up over time. No US-approved protocol.
Dosing reference
Chinese approvals set dosing guidelines, but there is no US label. Any use elsewhere is experimental. Verify current registration status.
Reference only — not a recommendation. Verify via primary sources.
Watch for
The pivotal data came from a single-ethnicity Chinese population, and there is no FDA approval. The numbers are real; the global evidence base is narrower than approved rivals.
Educational content — not medical advice.